Edarbi Tablets
Azilsartan Medoxomil
80mg
TAKEDA PHARMACEUTICALS U.S.A., INC.
| Pack size | 28's (7's Blister x 4) |
|---|---|
| Dispensing mode | POM |
| Source | USA |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 157.50 AED |
Available as:
Indications
Edarbi Tablets is used for:
Hypertension, alone or in combination w/ other antihypertensive agents.
Adult Dose
Adult: Initially 40 mg once daily. May be increased to a max of 80 mg once daily as necessary.
Elderly: No dose adjustment is necessary in elderly patients
Child Dose
Renal Dose
Renal Impairment
No dose adjustment is required with mild-to-severe renal impairment or end-stage renal disease.
Patients with moderate-to-severe renal impairment are more likely to report high serum creatinine values.
Administration
May be taken with or without food.
Contra Indications
Hypersensitivity. Pregnancy.
Precautions
Correct vol or salt depletion prior to administration. Renal (moderate to severe) & hepatic (severe) impairment. Pregnancy (1st trimester) & lactation. Childn <18 yr.
Monitor serum K in patients taking K-sparing diuretics, salt substitutes containing K & drugs that increase K levels (eg heparin) & creatinine levels in patients w/ renal impairment & type 2 DM. Aortic or mitral valve stenosis, hypertrophic obstructive cardiomyopathy.
Lactation: unknown whether distributed in breast milk, decide on alternate antihypertensive therapy or do not breastfeed
Pregnancy-Lactation
Pregnancy Category: C (1st trimester); D (2nd and 3rd trimesters)
Interactions
Reversibly increases serum conc & toxicity of lithium; attenuated antihypertensive effects & risk of worsening of renal function may occur w/ NSAIDs. Hyperkalemia w/ K-sparing diuretics & K supplements.
Adverse Effects
Side effects of Azilsartan Medoxomil :
1-10%
Diarrhea (2%)
<1%
Nausea, Asthenia, Fatigue, Muscle spasm, Dizziness, Postural hypotension, Cough
Mechanism of Action
Angiotensin II blocker; displaces angiotensin II from AT1 receptor and may lower blood pressure by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water absorption, and hypertrophic responses.
May induce more complete inhibition of renin-angiotensin system compared with ACE inhibitors; does not affect response to bradykinin.
Inhibits the pressor effects of an angiotensin II infusion in a dose-related manner.
Note
Edarbi 80mg Tablets manufactured by TAKEDA PHARMACEUTICALS U.S.A., INC.. Its generic name is Azilsartan Medoxomil. Edarbi is availble in United Arab Emirates.
Farmaco UAE drug index information on Edarbi Tablets is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.